Edward L Barnes1, Hans H Herfarth2, Michael D Kappelman3, Xian Zhang4, Amy Lightner5, Millie D Long2, Robert S Sandler6. 1. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: edward_barnes@med.unc.edu. 2. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Digestive Disease and Surgery Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. 6. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
BACKGROUND & AIMS: Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA. METHODS: We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital. RESULTS: Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%). CONCLUSIONS: In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
BACKGROUND & AIMS: Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA. METHODS: We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital. RESULTS: Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%). CONCLUSIONS: In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
Authors: Bo Shen; Victor W Fazio; Feza H Remzi; Aaron Brzezinski; Ana E Bennett; Rocio Lopez; Jeffrey P Hammel; Jean-Paul Achkar; Charles L Bevins; Ian C Lavery; Scott A Strong; Conor P Delaney; Wendy Liu; Marlene L Bambrick; Kerry K Sherman; Bret A Lashner Journal: Clin Gastroenterol Hepatol Date: 2006-01 Impact factor: 11.382
Authors: Stephanie Coward; Fiona Clement; Eric I Benchimol; Charles N Bernstein; J Antonio Avina-Zubieta; Alain Bitton; Mathew W Carroll; Glen Hazlewood; Kevan Jacobson; Susan Jelinski; Rob Deardon; Jennifer L Jones; M Ellen Kuenzig; Desmond Leddin; Kerry A McBrien; Sanjay K Murthy; Geoffrey C Nguyen; Anthony R Otley; Remo Panaccione; Ali Rezaie; Greg Rosenfeld; Juan Nicolás Peña-Sánchez; Harminder Singh; Laura E Targownik; Gilaad G Kaplan Journal: Gastroenterology Date: 2019-01-10 Impact factor: 22.682
Authors: Edward L Barnes; Hans H Herfarth; Robert S Sandler; Wenli Chen; Elizabeth Jaeger; Van M Nguyen; Amber R Robb; Michael D Kappelman; Christopher F Martin; Millie D Long Journal: Inflamm Bowel Dis Date: 2017-07 Impact factor: 5.325
Authors: Edward L Barnes; Bharati Kochar; Hans H Herfarth; Rachel W Winter; Millie D Long; Joshua R Korzenik; Silvia F Quevedo; Joseph A Galanko; Mark Koruda; Michael D Kappelman; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2020-03-06 Impact factor: 11.382
Authors: J P Segal; N S Ding; G Worley; S Mclaughlin; S Preston; O D Faiz; S K Clark; A L Hart Journal: Aliment Pharmacol Ther Date: 2016-12-23 Impact factor: 8.171
Authors: Victor Warren Fazio; Ravi P Kiran; Feza H Remzi; John Calvin Coffey; Helen Mary Heneghan; Hasan Tarik Kirat; Elena Manilich; Bo Shen; Sean T Martin Journal: Ann Surg Date: 2013-04 Impact factor: 12.969
Authors: Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands Journal: Inflamm Bowel Dis Date: 2014-02 Impact factor: 5.325
Authors: Phillip Fleshner; Andrew Ippoliti; Marla Dubinsky; Eric Vasiliauskas; Ling Mei; Konstantinos A Papadakis; Jerome I Rotter; Carol Landers; Stephan Targan Journal: Clin Gastroenterol Hepatol Date: 2008-04-18 Impact factor: 11.382
Authors: Ellen Cowherd; Matthew D Egberg; Michael D Kappelman; Xian Zhang; Millie D Long; Amy L Lightner; Robert S Sandler; Hans H Herfarth; Edward L Barnes Journal: Inflamm Bowel Dis Date: 2022-09-01 Impact factor: 7.290
Authors: Edward L Barnes; Parakkal Deepak; Poonam Beniwal-Patel; Laura Raffals; Maia Kayal; Marla Dubinsky; Shannon Chang; Peter D R Higgins; Jennifer I Barr; Joseph Galanko; Yue Jiang; Raymond K Cross; Millie D Long; Hans H Herfarth Journal: Crohns Colitis 360 Date: 2022-08-02